CO6571881A2 - Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer - Google Patents
Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncerInfo
- Publication number
- CO6571881A2 CO6571881A2 CO12195608A CO12195608A CO6571881A2 CO 6571881 A2 CO6571881 A2 CO 6571881A2 CO 12195608 A CO12195608 A CO 12195608A CO 12195608 A CO12195608 A CO 12195608A CO 6571881 A2 CO6571881 A2 CO 6571881A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- cxcr4
- cancer treatment
- humanized anti
- cxcr4 antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención se refiere a un nuevo anticuerpo humanizado aislado o los compuestos derivados o sus fragmentos funcionales, capaces de unirse con CXCR4, pero también de inducir un cambio conformacional de los homodímeros y/o heterodimeros de CXCR4.Más en particular, la presente invención se refiere a anticuerpos hz515H7, específicos de la proteína CXCR4, así como a su uso para el tratamiento de cáncer. Las composiciones farmacéuticas compuestas por tales anticuerpos y un proceso para la selección de tales anticuerpos también se hallan cubiertos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10290167A EP2371863A1 (en) | 2010-03-30 | 2010-03-30 | Humanized anti CXCR4 antibodies for the treatment of cancer |
US12/749,891 US8557964B2 (en) | 2008-10-01 | 2010-03-30 | Anti CXCR4 antibodies and their use for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6571881A2 true CO6571881A2 (es) | 2012-11-30 |
Family
ID=42556901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12195608A CO6571881A2 (es) | 2010-03-30 | 2012-10-30 | Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer |
Country Status (30)
Country | Link |
---|---|
US (1) | US9249223B2 (es) |
EP (2) | EP2371863A1 (es) |
JP (1) | JP5749330B2 (es) |
KR (1) | KR101838310B1 (es) |
CN (1) | CN102939306B (es) |
AR (1) | AR080740A1 (es) |
AU (1) | AU2011234458B2 (es) |
CA (1) | CA2794407C (es) |
CL (1) | CL2012002700A1 (es) |
CO (1) | CO6571881A2 (es) |
CY (1) | CY1115349T1 (es) |
DK (1) | DK2552963T3 (es) |
ES (1) | ES2469369T3 (es) |
HK (1) | HK1178910A1 (es) |
HR (1) | HRP20140502T1 (es) |
IL (1) | IL222198A (es) |
MA (1) | MA34175B1 (es) |
MX (1) | MX2012011206A (es) |
NZ (1) | NZ603182A (es) |
PL (1) | PL2552963T3 (es) |
PT (1) | PT2552963E (es) |
RS (1) | RS53405B (es) |
RU (1) | RU2595394C2 (es) |
SG (1) | SG184308A1 (es) |
SI (1) | SI2552963T1 (es) |
TN (1) | TN2012000466A1 (es) |
TW (1) | TWI549689B (es) |
UA (1) | UA106529C2 (es) |
WO (1) | WO2011121040A1 (es) |
ZA (1) | ZA201208015B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
MX2013004710A (es) * | 2010-10-27 | 2013-08-29 | Pf Medicament | Anticuerpos para el tratamiento de vih. |
US20140120555A1 (en) * | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
US11492383B2 (en) | 2011-06-24 | 2022-11-08 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
KR101809072B1 (ko) * | 2013-08-02 | 2017-12-14 | 화이자 인코포레이티드 | 항-cxcr4 항체 및 항체-약물 접합체 |
IL302725A (en) * | 2016-01-13 | 2023-07-01 | Regeneron Pharma | Rodents with an engineered DIVERSITY region of the heavy chain |
EP3471753A1 (en) | 2016-06-20 | 2019-04-24 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
US20210024873A1 (en) | 2018-03-27 | 2021-01-28 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
WO2020237221A1 (en) | 2019-05-23 | 2020-11-26 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
KR20230080460A (ko) | 2020-10-05 | 2023-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질을 농축시키는 방법 |
EP4005923B1 (de) | 2020-11-30 | 2023-08-30 | Bucher Leichtbau AG | Bordverpflegungsstation |
WO2023173011A1 (en) | 2022-03-09 | 2023-09-14 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424200A (en) | 1979-05-14 | 1984-01-03 | Nuc Med Inc. | Method for radiolabeling proteins with technetium-99m |
US4479930A (en) | 1982-07-26 | 1984-10-30 | Trustees Of The University Of Massachusetts | Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
US20050002939A1 (en) | 2002-12-23 | 2005-01-06 | Albert Zlotnik | Tumor killing/tumor regression using CXCR4 antagonists |
CA2536644A1 (en) * | 2003-06-30 | 2005-02-03 | Bio-Technology General (Israel) Ltd. | Antibodies and uses thereof |
BRPI0718197A2 (pt) * | 2006-10-02 | 2014-09-30 | Medarex Inc | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, e, métodos para preparar um anticorpo anti-cxcr4, para modular a atividade do cxcr4 em uma célula, e para estimular a mobilização de células tronco cd34+ da medula óssea para o sangue periférico em um indivíduo. |
FR2907341B1 (fr) * | 2006-10-18 | 2012-08-17 | Pf Medicament | Utilisation d'un anticorps anti-cd151 pour le traitement du cancer |
WO2009138519A1 (en) * | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
PL2119452T3 (pl) * | 2006-12-26 | 2021-03-08 | Centro De Inmunologia Molecular | Kompozycja farmaceutyczna zawierająca przeciwciało monoklonalne anty-cd6 do zastosowania w diagnostyce i leczeniu reumatoidalnego zapalenia stawów |
KR20100133012A (ko) * | 2008-05-14 | 2010-12-20 | 일라이 릴리 앤드 캄파니 | 항-cxcr4 항체 |
EP2172485A1 (en) * | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Novel anti CXCR4 antibodies and their use for the treatment of cancer |
EP2246364A1 (en) * | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anti CXCR4 antibodies for the treatment of HIV |
-
2010
- 2010-03-30 EP EP10290167A patent/EP2371863A1/en not_active Withdrawn
-
2011
- 2011-03-29 TW TW100110752A patent/TWI549689B/zh not_active IP Right Cessation
- 2011-03-30 WO PCT/EP2011/054945 patent/WO2011121040A1/en active Application Filing
- 2011-03-30 ES ES11711554.3T patent/ES2469369T3/es active Active
- 2011-03-30 KR KR1020127028361A patent/KR101838310B1/ko active IP Right Grant
- 2011-03-30 JP JP2013501835A patent/JP5749330B2/ja not_active Expired - Fee Related
- 2011-03-30 AR ARP110101043A patent/AR080740A1/es unknown
- 2011-03-30 US US13/637,198 patent/US9249223B2/en not_active Expired - Fee Related
- 2011-03-30 CN CN201180024677.3A patent/CN102939306B/zh not_active Expired - Fee Related
- 2011-03-30 UA UAA201212273A patent/UA106529C2/uk unknown
- 2011-03-30 MX MX2012011206A patent/MX2012011206A/es active IP Right Grant
- 2011-03-30 MA MA35329A patent/MA34175B1/fr unknown
- 2011-03-30 NZ NZ603182A patent/NZ603182A/en not_active IP Right Cessation
- 2011-03-30 EP EP11711554.3A patent/EP2552963B1/en not_active Not-in-force
- 2011-03-30 AU AU2011234458A patent/AU2011234458B2/en not_active Ceased
- 2011-03-30 RU RU2012145232/10A patent/RU2595394C2/ru not_active IP Right Cessation
- 2011-03-30 PL PL11711554T patent/PL2552963T3/pl unknown
- 2011-03-30 CA CA2794407A patent/CA2794407C/en not_active Expired - Fee Related
- 2011-03-30 RS RS20140343A patent/RS53405B/en unknown
- 2011-03-30 SG SG2012071882A patent/SG184308A1/en unknown
- 2011-03-30 SI SI201130181T patent/SI2552963T1/sl unknown
- 2011-03-30 DK DK11711554.3T patent/DK2552963T3/da active
- 2011-03-30 PT PT117115543T patent/PT2552963E/pt unknown
-
2012
- 2012-04-04 ZA ZA2012/08015A patent/ZA201208015B/en unknown
- 2012-09-26 TN TNP2012000466A patent/TN2012000466A1/en unknown
- 2012-09-27 CL CL2012002700A patent/CL2012002700A1/es unknown
- 2012-09-27 IL IL222198A patent/IL222198A/en not_active IP Right Cessation
- 2012-10-30 CO CO12195608A patent/CO6571881A2/es active IP Right Grant
-
2013
- 2013-05-16 HK HK13105830.8A patent/HK1178910A1/xx not_active IP Right Cessation
-
2014
- 2014-06-02 HR HRP20140502AT patent/HRP20140502T1/hr unknown
- 2014-06-11 CY CY20141100422T patent/CY1115349T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6571881A2 (es) | Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer | |
CO6390114A2 (es) | Anticuerpos anti cxcr4 para el tratamiento | |
CO6801633A2 (es) | Uso de las celulas t modificadas por receptor de antigeno quimerico para tratamiento de cancer | |
DOP2014000007A (es) | Proteinas de union a antigeno de tnf-alfa con union a fcrn incrementada | |
AR054539A1 (es) | Nuevos anticuerpos anti- madcam | |
ECSP10010475A (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
PE20160993A1 (es) | Nuevos anticuerpos anti-dpep3 y metodos de uso | |
EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201400579A1 (ru) | Антитела к il-36r | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
DOP2011000333A (es) | Inmunoglobulina con dominio variable dual y usos de la mismas | |
CL2012002782A1 (es) | Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros. | |
AR090923A1 (es) | Anticuerpos anti-il-23 | |
UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
AR073072A1 (es) | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano | |
ECSP099572A (es) | Anticuerpos monoclonales anti-cxcl13 | |
UY32917A (es) | Moléculas de unión a dll-4 | |
UY34116A (es) | El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico | |
CL2007003191A1 (es) | Compuestos derivados de pirimido-piridona, inhibidores de las proteina quinasas; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como artritis, sindrome de colon irritable, sindrome disneico agudo del adulto, epoc y para el | |
PE20150212A1 (es) | Anticuerpos anti-trka con propiedades inhibitorias mejoradas y sus derivados | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
ECSP099341A (es) | Nuevos anticuerpos antiproliferativos | |
ECSP14029713A (es) | Moléculas de unión il-6 | |
BR112014013138A2 (pt) | anilinas substituídas como antagonistas de ccr(4) | |
ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |